Citi analyst Samantha Semenkow initiated coverage of Biohaven (BHVN) with a Buy rating and $28 price target The company is therapies across neuroscience, immunology, and oncology, the analyst tells investors in a research note. Citi views the stock’s valuation as “de-risked” into the troriluzole FDA action date.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN: